Round led by Avidity Partners. Platform usage, ARR, & contracted ARR all grew by more than 2.5x year-over-year.

SAN FRANCISCO, Oct. 15, 2026 — Sirona Medical, Inc. (“Sirona”), the market leader in cloud-native radiology software, today announced $40 million in Series D financing led by Avidity Partners, with participation from 8VC, GreatPoint Ventures, KLT Holdings, and other new and existing investors. The round funds Sirona’s operating plan indefinitely.

Sirona’s RadOS platform unifies PACS, reporting, diagnostic viewing, worklist, and workflow AI on a single cloud and AI-native platform. Since its public launch in November 2023, Sirona has grown to dozens of contracted customers across hundreds of integrated sites, with more than 12 million primary imaging exams per year under contract.

Growth (as of September 30, 2026)

• Revenue: 2.5x year-over-year
• Contracted ARR: 2.7x year-over-year
• Platform Usage: PACS archive usage grew 2.5x and diagnostic reports submitted through the platform grew 2x year-over-year.
• Contracted Usage Growth: Sirona is under contract to onboard over 1,000 additional radiologists over the next twelve months.
• Average Deal Size: Mean new-customer contracted ARR reached $1.07 million on a trailing twelve-month basis, with mean total contract value reaching $5.10 million.

Use of Proceeds

• Cash-Flow Positivity: Series D funds Sirona indefinitely.
• Client Services Organization: Hired Anders Osterholm, a 25-year Sectra veteran to lead Sirona’s Client Services Organization. This includes opening new offices in Burlington, Vermont, and Cincinnati, Ohio, as Sirona expands its U.S.-based implementation and 24×7 support teams.
• Sirona Cortex: Commercialization of Cortex, Sirona’s agentic AI orchestration layer. 
• The Sirona Network: Sirona has brought hundreds of radiologists onto a single cloud-native infrastructure, with more than half of Sirona customers collaborating in some way through the RadOS platform today. Over 2027, the company will refine tooling with the help of its private practice and health system partners that will allow them to better leverage the Sirona Network.
• International: Launch of Sirona Global, the company’s international program, before the end of 2026. Sirona Global will expand the company’s operational and commercial footprint into international markets including the UK, EU, South Africa, New Zealand, Australia, and more.

“Sirona’s mission has always been to accelerate the transition to AI-powered healthcare globally,” said Cameron Andrews, Founder and President of Sirona Medical. “We pioneered a new category of software in 2018 to accomplish this, and thanks to the confidence of our customers, partners, and investors, Sirona now has the permanent capital necessary to deliver this vision to tens of millions of patients a year and at global scale.”

“As the industry confronts a radiology staffing crisis, Sirona’s customers are growing capacity faster than any other defined segment of the U.S. radiology market,” said Ken Kaufman, Chief Executive Officer of Sirona Medical. “We’re proud of the capacity we helped our customers build this year, and look forward to deploying RadOS to more practices, hospitals, health systems, and international markets in 2027.”

“Sirona is the category-defining company in cloud-native radiology,” said Jacob Garfield, Partner and Managing Director at Avidity Partners. “Sirona’s customers are achieving above-market volume growth in their practices and delivering care at a faster clip.”

Over the coming months, Sirona will release “Built on Sirona,” a series of dozens of customer stories and technical deep dives exploring the RadOS architecture in depth. The series will illustrate how practices are using the RadOS platform to reimagine the process of radiology for the AI-age and will highlight groups that have used RadOS to solve some of the most important economic and operational challenges in radiology today in ways that could only have been Built on Sirona. The introduction to this series is available now at sironamedical.com/built-on-sirona.

About Sirona Medical, Inc.

Sirona Medical is the global leader in AI-native radiology workflow software. The company’s cloud-native platform, RadOS, is the industry’s first unified radiology operating system, bringing together the diagnostic viewer, reporter, PACS archive, worklist, and AI into a single efficient clinical workflow. Sirona enables radiologists to work faster, deploy AI more effectively, and deliver better care for patients from anywhere. Sirona is backed by roughly $150 million in venture capital and trusted by some of the largest radiology practices, hospitals, and health systems globally. For more information, visit www.sironamedical.com.

SOURCE Sirona Medical

With early traction among major payers and provider groups, Otter Health’s AI-powered model helps reduce unnecessary care and variation without traditional prior authorization.

WASHINGTON, Oct. 15, 2026 — Otter Health, a healthcare technology company building a model for smarter utilization management and quality that dismantles the administrative arms race, today announced its official launch alongside $8 million in seed funding co-led by Fika Ventures and Evidenced, with participation from Slow Ventures, Metrodora, CoFound Partners, Layout Ventures, Patient Capital, and Semper Virens.

Otter Health delivers a new platform for payers and providers to collaboratively align delivery to the gold standard of care. The company’s AI-powered, EHR-agnostic platform helps healthcare delivery organizations and payers identify and reduce low-value, non-evidence based care decisions in real time, replacing the friction of traditional prior authorization with a more transparent approach, grounded with precision against clinical evidence and guidelines. Through immediate and ongoing visibility into care patterns, peer benchmarking and targeted clinician engagement, Otter Health helps align clinicians, administrators and medical management teams around care appropriateness, while surfacing opportunities to improve quality and reduce unnecessary spending.

“Healthcare has spent decades trying to contain spend through administrative friction, creating a system that often puts payers and providers on opposite sides of the same problem,” said Keith Florance, co-founder and CEO of Otter Health. “The real goal was never the authorization step itself, but instead was helping organizations deliver more appropriate, evidence-based care at scale. We’re building utilization management and quality around real-time clinical intelligence rather than administrative chokepoints. By giving payers and providers a shared view of the gold standard for quality, we can reduce low-value care, improve outcomes, and create a more collaborative approach to healthcare affordability.”

Historically, prior authorization has served as healthcare’s primary tool for managing utilization and cost, while aggravating physician-level decision making. The authorization process became one of the industry’s mechanisms for controlling care along with risk-adjusted claims analyses that clashed with clinicians. As a result, the underlying goal of ensuring that patients receive appropriate, evidence-based treatment was obscured.

Otter Health takes a different approach by providing continuous, real-time comparison to the evidentiary standard across a much broader range of clinical decisions, including referrals, outpatient procedures, pathway adherence and care transitions. By giving payers and providers a shared view of evidence-based delivery, the platform’s AI helps identify opportunities to reduce low-value care, improve quality, create greater accountability and lower costs without relying on administrative friction as the primary means of control. This enables a more collaborative approach to utilization management, aligning payers and providers around the same clinical and financial goals.

“We have a great opportunity to support clinicians in the thousands of decisions they make every day,” said Kate Goodrich, Executive in Residence at Optum, former Humana Chief Medical Officer and Director of the CMS Center for Clinical Standards and Quality. “Creating greater visibility into evidence-based practice through guidance and tools can empower a more proactive and collaborative approach in supporting clinicians to deliver the highest quality care while effectively managing cost and improving access.”

Otter Health is already working with multiple healthcare organizations across the payer and provider ecosystem to identify opportunities to reduce low-value care, improve evidence-based decision-making and create a more collaborative approach to utilization management. They’ve shown that by removing prior authorization with the right engagement through the Otter Health platform, they can limit non-concordant decisions to less than 5% and capture substantial savings on low-value care that prior authorization never touched.

Otter Health launches amid growing scrutiny of traditional prior authorization. According to the American Medical Association, physicians complete nearly 40 prior authorizations per week, 93% report that prior authorization delays necessary care, and 82% say it can cause patients to abandon treatment altogether. At the same time, Otter estimates that over 60% of low-value healthcare spending occurs outside traditional authorization controls, representing millions of dollars in avoidable annual spending per 1,000 lives. By evaluating care decisions across outpatient procedures, referrals, pathway adherence, and post-acute transitions, Otter provides a more continuous, real-time approach to managing care appropriateness as value-based care shifts utilization risk to providers.

“Healthcare has spent decades investing in the mechanisms used to control utilization,” said Bryan Sivak, Managing Partner of Evidenced and former CTO of the US HHS. “Otter Health is taking a different approach by creating better visibility into care appropriateness itself. By helping payers and providers operate from the same evidence-based understanding of clinical decisions, the company is creating an alternative to the conflicts that historically defined utilization management. We believe that kind of transparency can reduce waste, improve quality and fundamentally reshape how healthcare organizations manage quality and clinical variation.”

About Otter Health

Otter Health is a healthcare technology company reimagining utilization management and quality by replacing administrative friction with real-time clinical intelligence. The company’s AI-powered platform provides payers and providers with a shared, evidence-based view of care appropriateness, helping reduce low-value care, improve quality and lower unnecessary healthcare spending. Founded by healthcare operators and clinicians with expertise in utilization management, clinical quality and healthcare technology, Otter Health is backed by Fika Ventures, Evidenced, Slow Ventures, Metrodora, CoFound Partners, Layout Ventures, Patient Capital and Semper Virens. For more information, visit www.otter-health.com.

CONTACT: [email protected]

SOURCE Otter Health

DENVER, Oct. 15, 2026 — Bow River Capital (“Bow River”), a Denver-based alternative asset manager, announced today that Greg Hiatrides, Head of Bow River’s Private Equity team, has been appointed Chief Executive Officer. Hiatrides succeeds Blair Richardson, who founded the firm and has led it as Chief Executive Officer for 23 years. Richardson will transition to Bow River’s Chairman, continuing to forge investor relationships and supporting the firm’s strategic direction.

Under Richardson’s leadership, Bow River expanded into a multi-strategy investment platform spanning private equity, private credit, real estate, and venture capital; the firm offers investors both closed end and evergreen strategies.

Hiatrides, who joined Bow River in 2015 and has more than 20 years of investment and advisory experience, built the firm’s highly successful private equity platform and has led some of its largest and most complex transactions. Hiatrides started his investment career in New York; prior to joining Bow River, he worked at KPMG Corporate Finance (formerly St. Charles Capital).

“I have often said that Bow River should be a forever firm, and today we’re announcing an important step in making that a reality,” said Richardson. “It is the right time, and Greg is the right leader to move our business forward. He brings a pragmatic, effective commitment to investment performance, a sound grasp of risk management and, most importantly, a deep appreciation of the fiduciary responsibility we have to our investors.”

“I am honored to step into this role and grateful to Blair and our talented team at Bow River for building a firm with such a strong foundation,” said Hiatrides. “Our number one priority remains investment excellence, encompassing both the financial and relational value we produce for our limited partners and portfolio partners. We look forward to evolving Bow River’s recognized standing as a leading, scaled boutique alternative asset manager – providing unique access to the lower middle market across complementary fund strategies.”

About Bow River Capital

Bow River Capital is a Denver-based alternative asset manager investing across private equity, private credit, real estate, and venture capital. For more than two decades, the firm has partnered with lower middle market management teams and property owners to build enduring businesses and properties with a focus on the Rodeo Region, a geographic footprint encompassing 14 states in the Rocky Mountain West and Southwest. Bow River is guided by a commitment to investment excellence, disciplined underwriting and close alignment with its investors.

Learn more at www.BowRiverCapital.com

Contact: Ashley Dzaman, 303-861-8466

SOURCE Bow River Capital

NEW YORK, 15 octobre 2026 — OrbiMed, une société d’investissement mondiale de premier plan dans le secteur de la santé, est heureuse d’annoncer qu’elle a levé 3 milliards de dollars d’engagements pour deux nouveaux fonds de capital-investissement : OrbiMed Private Investments X et OrbiMed Asia Partners VI.

OrbiMed Private Investments X a levé plus de 1,9 milliard de dollars pour investir dans des opportunités de capital-risque dans les sciences de la vie aux États-Unis et en Europe. OrbiMed Asia Partners VI a levé plus d’un milliard de dollars pour investir dans des opportunités de capital-risque et de croissance dans le secteur de la santé en Asie. Ces deux fonds visent à créer des entreprises de soins de santé de premier plan axées sur les produits biopharmaceutiques, les dispositifs médicaux, les diagnostics et les services de santé s’appuyant sur la technologie.

« Il n’y a jamais eu de moment plus propice pour investir dans l’innovation en sciences de la vie », a déclaré Carl Gordon, associé gérant d’OrbiMed. « L’intelligence artificielle, la multiplication des nouvelles modalités thérapeutiques et l’émergence de la Chine comme puissance biotechnologique multiplient les opportunités de développer des traitements transformateurs. Nous avons hâte d’aider les entrepreneurs à transformer ces avancées en entreprises leaders dans le secteur de la santé. »

OrbiMed est dirigée par 20 partenaires et soutenue par une équipe de plus de 150 professionnels possédant une expertise complémentaire en matière d’incubation d’entreprises, de stratégie, d’opérations et de finance. L’entreprise opère depuis 12 sites à travers le monde, répartis sur les principaux marchés de la santé.

Les investisseurs de ces nouveaux fonds comprennent un large éventail d’institutions médicales, de fonds de dotation universitaires, de fondations, de fonds de pension, de fonds souverains et de family offices.

« Nous sommes reconnaissants du soutien continu de nos nombreux investisseurs de longue date », a déclaré Carter Neild, associé gérant d’OrbiMed. « Nous travaillerons sans relâche au cours des prochaines années pour répondre à leurs attentes élevées. »

À propos d’OrbiMed
OrbiMed est une société d’investissement de premier plan dans le secteur de la santé, avec plus de 21 milliards de dollars d’actifs sous gestion. OrbiMed investit à l’échelle mondiale dans l’ensemble du secteur de la santé, des start-ups aux grandes multinationales, par le biais de fonds de capital-investissement, de fonds d’actions cotées en bourse et de fonds de redevances/crédit. OrbiMed aspire à être un fournisseur de capitaux de choix, en proposant des solutions de financement sur mesure et des ressources d’équipe mondiales importantes pour aider à bâtir des entreprises de soins de santé de classe mondiale. L’équipe d’OrbiMed, composée de plus de 150 professionnels, est basée à New York, Londres, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya et sur d’autres marchés mondiaux clés. Pour plus d’informations, veuillez visiter www.orbimed.com.

NEW YORK, Oct. 15, 2026 — OrbiMed, a leading global healthcare investment firm, is pleased to announce that it has raised $3 billion in commitments for two new private equity funds: OrbiMed Private Investments X and OrbiMed Asia Partners VI.

OrbiMed Private Investments X raised over $1.9 billion to invest in U.S. and European life sciences venture capital opportunities. OrbiMed Asia Partners VI raised over $1 billion to invest in healthcare growth equity and venture capital opportunities across Asia. Both funds seek to build leading healthcare companies focused on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.

“There has never been a more exciting time to invest in life sciences innovation,” said Carl Gordon, a managing partner of OrbiMed. “AI, a proliferation of new therapeutic modalities and China’s emergence as a biotechnology powerhouse are expanding the opportunities to develop transformative treatments. We look forward to helping entrepreneurs turn these advances into leading healthcare companies.”

OrbiMed is led by 20 partners and supported by a team of over 150 professionals with complementary expertise in company incubation, strategy, operations and finance. The firm operates from 12 global locations across key healthcare markets.

Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.

“We are grateful for the continued support of our many long-standing investors,” said Carter Neild, a managing partner of OrbiMed. “We will work tirelessly over the coming years to meet their high expectations.”

About OrbiMed
OrbiMed is a leading healthcare investment firm with over $21 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 150 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets. For more information, please visit www.orbimed.com.

SOURCE OrbiMed

Pantera Capital leads the round with participation from Circle Ventures, New Form, gumi Cryptos Capital, Borderless Capital and Ari Rubenstein, CEO of GTS

• Tokenization is rapidly moving private-market funds onto digital rails, but liquidity has not kept pace. Traditional fund structuring forces investors to face long settlement and redemption cycles. Fission helps close that gap by giving eligible investors faster access to capital.
• Funding will expand Fission’s liquidity capacity, support a broader range of tokenized private-market and semi-liquid funds, and deepen integrations across the digital investment ecosystem.
• Fission has already processed millions of dollars in redemptions, demonstrating growing demand for more flexible liquidity across tokenized private-market funds.

NEW YORK, Oct. 15, 2026 — Fission, a blockchain-enabled financial technology company building liquidity infrastructure for tokenized investment funds, today announced it has closed a $10 million Series A funding round led by Pantera Capital and backed by a group of investors spanning traditional finance and digital assets.

Investment funds are rapidly moving on-chain. Tokenization has already transformed how fund interests can be issued, distributed and settled, but much of the underlying market structure remains unchanged. Tokenized funds still rely on periodic redemption windows, limited secondary liquidity and restrictive financing structures.

Fission is building the liquidity layer designed to change that.

The company enables investor liquidity for supported tokenized fund products, allowing eligible holders to access capital without waiting for traditional fund redemption cycles. Fission supports a growing universe of tokenized funds across asset classes including private credit, alternatives and other institutional investment products. The company has already processed millions of dollars in transactions and is expanding its capacity through both traditional and on-chain sources of capital.

“Putting funds on-chain is only the beginning,” said Jonathan Shaffer, Founder and CEO of Fission. “The real promise of tokenization is creating fundamentally better markets around these assets: broader distribution, continuous liquidity and the ability to use fund interests as collateral in lending markets. Whether a fund is private or simply constrained by traditional liquidity structures, Fission is building the technology that makes those assets more liquid, transferable and useful across financial markets.”

Fission’s platform is purpose-built for institutional and permissioned markets, with infrastructure designed around the investor eligibility, transfer restrictions and compliance requirements governing regulated investment products. This allows Fission to bring on-chain liquidity to these assets while preserving the controls required by securities markets.

The new capital will support Fission’s continued expansion across asset coverage, liquidity capacity and institutional integrations.

“Investment funds are moving onto digital rails and liquidity is one of the critical pieces required for that transition to reach its full potential,” said Franklin Bi, General Partner at Pantera Capital. “Fission is building infrastructure that will help transform tokenized funds from representations of traditional products with legacy constraints into fundamentally more liquid and productive assets.”

The round adds Pantera Capital, Circle Ventures, Borderless Capital and Ari Rubenstein to Fission’s investor base, alongside existing backers including New Form, gumi Cryptos Capital, Anthony Scaramucci, Manhattan Venture Partners, Reflexive Capital and Lattice Capital.

For more on Fission’s infrastructure and its vision for the future of on-chain investment funds, visit Fission: The Liquidity Layer for Tokenized Funds.

About Fission

Fission is building the liquidity infrastructure for the next generation of digital investment funds. Its team brings experience from institutions including Point72 and Securitize, spanning institutional trading, private-market distribution, tokenization and regulated securities markets. Fission’s mission is to make investment funds more liquid, accessible and financeable by powering the digital infrastructure required for these products to scale globally.

About Pantera Capital

Pantera Capital is an institutional investment firm focused on blockchain technology, digital assets, and the companies building the digital economy. As a multi-stage partner, Pantera backs companies from their earliest seed rounds through the public markets, providing capital and expertise to the founders building the defining companies of the frontier. In 2013, the firm launched the first blockchain fund in the United States, when bitcoin traded at $65. It went on to launch the first exclusively blockchain venture fund and, in 2017, the first early-stage token fund. Today Pantera invests across venture, hedge, and passive strategies, drawing on more than a decade of experience supporting companies through multiple market cycles. The Pantera Bitcoin Fund has returned 102,760% since inception and billions of dollars to its investors.

Fission.xyz

SOURCE Fission Labs

Raises $1.85 billion to help businesses get more value from every dollar, hour and token

NEW YORK, Oct. 15, 2026 — Ramp today announced a $1.85 billion primary financing round led by Dragoneer Investment Group, valuing the company at $60 billion. Thrive Capital, Founders Fund, Sands Capital, and Avenir Growth co-led the round, with participation from additional investors including: Capital International, Fidelity Management & Research Company, T. Rowe Price, D1 Capital Partners, Greenoaks, ICONIQ, GIC, 8VC, 1789 Capital, Alpha Wave Global, Ontario Teachers’ Pension Plan, Coatue, D.E. Shaw, Definition Capital, FirstMark, General Catalyst, Generation Investment Management, Glade Brook Capital Partners, Khosla Ventures, Lightspeed Venture Partners, Pinegrove Opportunity Partners, Soma Capital, and Stripes.

Ramp now generates more than $2 billion in annualized revenue¹, with positive cash flow. The company’s revenue is growing 25% faster now than it was at the same time last year. Finally, Ramp’s enterprise business continues to grow, with a 113% year-over-year increase in customers generating over $100,000 in revenue.

“Ramp is the kind of company we love to back at Dragoneer. It’s already a market leader with a deep, durable moat, and it’s still growing incredibly fast,” said Christian Jensen, Partner at Dragoneer. “In just a few years, Ramp has become a much broader financial operations platform, with AI deeply embedded in how the company builds and operates. We believe Ramp is well on its way to becoming one of the defining companies of this era.”

“We first invested in Ramp in 2023 as it was becoming the obvious choice for finance teams. With AI, Ramp’s platform is becoming the obvious choice to automate the entire office of finance,” said Barron Martin, Managing Partner at Sands Capital. “Three years and multiple rounds later, we believe the opportunity is more compelling now than when we first invested, and we’re proud to deepen our partnership with Eric, Karim, and the team.”

Customers get more value from every dollar with Ramp

More than 85,000 companies use Ramp to manage over $275 billion in annualized purchase volume, up 175% year over year. Together, they save more than $1 billion every month. The median customer now saves 7.5%, up from 5% a year ago, and completes transactions with 22% less manual work. That’s 50% more savings on every dollar spent than a year ago, giving customers more money to put back into their businesses.

As Ramp saves customers more time and money, they trust it with more of their financial operations — from paying bills and closing the books to collecting revenue. The majority of customers now use two or more Ramp products, and a quarter use three or more. As AI becomes a bigger part of companies’ spending, Ramp’s opportunity to deliver more value continues to grow.

“At Uber’s scale, small inefficiencies add up,” said Justin Reyhl, Head of Global Travel & Expense at Uber. “We want our people focused on reimagining the way the world moves for the better, and we want every dollar we spend to advance the business. Ramp helps us scale our T&E operations without added layers of work, while keeping the spend under control.”

Ramp helps businesses earn a higher return on intelligence

Ramp has spent seven years helping businesses get more from every dollar. Now it’s bringing that same focus to AI.

Businesses need AI that gets work done — and a way to see what that work costs. Ramp is bringing AI tools and financial controls together so teams can put each dollar and token toward what works, compounding those gains into greater productivity and faster growth.

Recent launches include:

• Glass is a model-agnostic, collaborative AI workspace where knowledge compounds.
• Ramp Accounts Receivable automates the work between a signed contract and collected cash, including invoice creation, payment follow-up, cash application, and revenue recognition.
• AI Token Spend Management gives finance and technical teams one place to understand and control AI spending across providers, teams, models, users, and API keys.
• Router.com cuts companies’ inference costs up to 40% by routing requests based on performance and cost through one endpoint.

“We obsess over saving our customers time and money. That’s why we’re growing faster at more than twice the size we were a year ago,” said Eric Glyman, co-founder and co-CEO of Ramp. “AI opens up much more of the work it takes to run a company. Our opportunity is to get that work done at less cost. We want to help every business run better with AI.”

“Ramp’s Token Spend Management helped us cut monthly AI spend by 17.5%,” said Greg Cooley, Controller at AngelList. “That gives us more room to invest in work that moves the business forward. We want to keep expanding what we do with AI, and Ramp helps us make every dollar count.”

“When you’re building an AI company, the models your engineers can use and the cost of running them directly affect what you can build,” said Alex McLeod, Chief Technology Officer at Serval. “Router gives our team access to models across providers through one API and automatically optimizes costs. For our coding agents, that’s meant cutting inference costs nearly in half—savings we can put back into building.”

Key Company Stats as of October 1, 2026

• Over $2 billion in annualized revenue, with positive cash flow.
• 85,000+ customers, including Visa, Uber, Shopify, Robinhood, Fanatics, Notion, Cursor, The Denver Broncos, and The Boys and Girls Club.
• Over $275 billion in annualized purchase volume.*
• Median customer: 7.5% savings and 16% revenue growth in their first year.

With this round, Ramp has raised approximately $5 billion in total equity financing.

About Ramp

Ramp is how companies save time and money on every dollar they spend. It’s the smart financial infrastructure behind every card swipe, invoice, and reimbursement – streamlining approvals, processing payments, and closing the books automatically. More than 85,000 organizations, from family farms and space startups to the Fortune 100, use Ramp to save over $1 billion a month and over a year’s worth of work every hour. The median customer using Ramp achieved 7.5% savings on expenses and 16% revenue growth in their first year. Founded in 2019, Ramp powers over $275 billion in purchases annually. Learn more at www.ramp.com.

* Ramp does not include bank transfers or non-monetized payments when calculating Total Purchase Volume.

CONTACT: [email protected]

SOURCE Ramp

PORTLAND, Ore., Oct. 15, 2026 — Mueon Corporation, a semiconductor systems company building a new modular foundation for AI and hyperscale computing, today announced $65 million raised in a Series A. Maverick Silicon led the financing, with participation from Intel Capital, Geodesic Alliances Fund, Oregon Venture Fund, M-Ventures, Wellington Capital, IQT, and Defined.

The new capital marks Mueon’s next phase of growth after emerging from stealth with a $15.5 million seed round in 2025, bringing capital raised to over $80M to date. The company is using the Series A funding to expand its engineering and operations teams, transition Cubelets™ from the platform development phase towards broader system validation and production readiness, and deepen its growing customer engagements.

“This financing gives us the scale to bring the next generation of compute and memory system-scale integration to market,” said Wilfred Gomes, co-founder and CEO of Mueon Corporation. “Mueon’s architecture is built to move past today’s rack-level constraints and deliver the kind of density the rest of the industry is only beginning to chart a path toward.”

Exponential™ Computing Platform Built for the System Scale Era

Mueon’s core architectural concept is Cubelets™: modular, three-dimensional (3D) compute + memory building blocks. Rather than optimizing each subsystem independently, Mueon is developing the platform around the data movement, power density, and deployment constraints that increasingly define AI infrastructure economics. Cubelets™ densify compute at the system level, reducing the physical distance data has to travel and the power cost that comes with moving it, without requiring the sprawl of a traditional server rack. The architecture treats packaging, interconnect, power, and thermals as first-class design variables rather than separate problems to solve after the fact, extending beyond any single accelerator technology.

Since its seed financing, Mueon has broadened the program across four execution tracks:

• Silicon and system architecture: Advancing the compute, memory, and interconnect architecture required to turn Cubelets™ into scalable 3D systems.
• Advanced integration: Developing packaging, power-delivery, and thermal approaches needed for much higher compute density without simply reproducing rack-level complexity at a smaller scale.
• Software and system orchestration: Building the software layer needed to make modular hardware usable through familiar AI frameworks and deployment workflows.
• Ecosystem validation: Working with technology, manufacturing and industry partners to validate components, integration choices and the path from prototype to production.

“The Mueon team combines deep expertise in the technologies that define modern data centers with the experience to deploy those technologies at system scale,” said Manish Muthal, Sr. Managing Director at Maverick Silicon.

As part of the financing, Manish Muthal will join Mueon’s board of directors alongside Intel Capital Managing Director Srini Ananth.

“Mueon is continuing to reimagine data-center design at the fundamental level,” said Srini Ananth, Managing Director at Intel Capital. “By bringing compute, memory, power delivery, and thermal management together into a single, integrated system, the team is building a path to scale AI infrastructure with better economics and efficiency, and this round reflects the engineering depth and ecosystem required to bring that vision to market.”

Why the Architecture Matters Now

Mueon is targeting up to 10X gains in power and cost efficiency within the same rack footprint, with the architecture designed to scale toward megawatt-class density as demand grows.

“Mueon’s Cubelets™ architecture creates new possibilities for partners such as d-Matrix,” said Sudeep Bhoja, Co-founder and CTO of d-Matrix. “Combined with in-memory compute, a modular system architecture can enable smaller, denser infrastructure tailored for AI workloads and allow us to experiment, optimize, and deploy at new scales.”

“Large-scale data centers have been constrained by power and cooling limits for years,” said Rohit Vidwans, Co-CEO of Ampere Computing, now part of SoftBank. “Mueon’s modular approach rethinks the physical building blocks of infrastructure. We are pleased to work with the Mueon team as it de-risks the technology on the path toward production.”

About Mueon

Mueon Corporation is developing an Exponential™ Computing Platform for AI and hyperscale infrastructure. Its Cubelets™ architecture uses modular, stackable building blocks to tightly integrate compute, memory, interconnect, power delivery, and thermal management to increase deployable compute density while reducing system complexity, power, and infrastructure overhead.

Headquartered in Portland, Oregon, Mueon brings together engineers and industry leaders with experience across CPU and GPU architecture, memory systems, advanced packaging, high-speed I/O, power delivery, thermal engineering, and large-scale system design. For more information, visit mueon.com.

Media Contact
[email protected] 

SOURCE Mueon Corporation

Pioneer of The Healthy Skin Movement™ to present its patented technology platform and $5 million SEED capital opportunity at the Global Capital Network Investor Conference on October 15, 2026.

DALLAS and FORT WORTH, Texas, Oct. 14, 2026 — Hi-TECH Beauty Labs, Corp. (HTBL) announced the issuance of U.S. Patent No. 12,642,834 B2 for B3 Technology®, a 100% natural botanical innovation designed to address problem skin without benzoyl peroxide, salicylic acid, adapalene or retinol.

Built at the intersection of Silicon Valley high technology, skin cell science, and botanicals, HTBL is advancing skincare innovation through its brand SkinKick® and a proprietary technology platform.

HTBL will present its commercialization strategy and capital opportunity at the Global Capital Network Investor Conference on October 15, 2026, in Newport Beach, California.

From Silicon Valley to Skincare

Founded by Matthew J. Schirle, a former international semiconductor executive and Chemical Engineer, HTBL applies engineering principles and root-cause analysis to skincare challenges. Chief Science Officer, Dr. D. William Provance, PhD, is the inventor of HTBL’s technologies, including B3 Technology®.

Their exclusive SkinViNO™ Process Innovation — Vitamins, Nutrients and Omegas — guides ingredient selection through a focus on skin-cell biology.

SkinKick® brings this approach to consumers with its CLEAR + RENEW + PROTECT philosophy for skin and barrier care.

B3 Technology® — A Patented Botanical Platform

Issued June 2, 2026, U.S. Patent No. 12,642,834 B2 protects B3 Technology®, incorporating Black Willow Bark (Salix nigra), Cat’s Claw (Uncaria tomentosa) and Dragon’s Blood (Croton lechleri).

The HTBL technology platform supports alternatives to harsh acid-based formulations for problem skin and aging skin enabling potential licensing opportunities with established beauty companies.

Pioneering The Healthy Skin Movement™

“We didn’t enter the beauty industry to create another harsh acid-based skincare brand. We entered to challenge conventional thinking and deliver outrageously effective and natural products” said Schirle. “We treat your skin like a garden and not a test ground for a chemical factory”.

“My semiconductor background taught me to identify root causes, challenge assumptions and develop better solutions. Dr. Provance’s inventions bring that vision to life.

“We recognized and leveraged the fact that the architecture of a semiconductor memory cell is nearly identical to that of a human skin pore which led to the 2-Step Acne Model Innovation.

“This first patent is an important milestone, but our vision is bigger: pioneering The Healthy Skin Movement™ and challenging the belief that “pain is gain” in skincare.

“Our mission is to Replace Pain with Performance™ and deliver Self-Esteem in a Bottle™.”

Technology, Commercialization and Growth

HTBL plans to scale SkinKick® while licensing proprietary technologies to beauty and personal-care companies.

The company is pursuing a $5 million SEED Round to accelerate digital commerce, distribution and technology commercialization.

Schirle will present HTBL’s investment opportunity on October 15, 2026, at the Renaissance Newport Beach Hotel.

The Global Capital Network conference connects emerging companies with investors and capital providers.

ABOUT HI-TECH BEAUTY LABS

Born in Dallas, Texas, Hi-TECH Beauty Labs, Corp. (HTBL) is pioneering The Healthy Skin Movement™ with its technology platform built at the intersection of Silicon Valley high TECHNOLOGY, skin cell SCIENCE, and natural BOTANICALS.

Powered by its proprietary SkinViNO™ Process and patented B3 Technology®, HTBL is reimagining skincare through Naturally Smart® innovations that are replacing industry-standard harsh AHA acids and harmful chemicals — including industry darlings benzoyl peroxide and retinol — with clinically studied, outrageously effective, 100% natural botanical technologies.

Its flagship brand, SkinKick®, embodies BEAUTY REIMAGINED — they CLEAR acne-prone skin, RENEW aging skin, and PROTECT the skin barrier – all at the same time. Developed for all generations, including those with sensitive skin and the emerging “Sephora Kids” gen alpha audience, SkinKick® delivers Self-Esteem in a Bottle™ — because healthier skin inspires the confidence that changes lives.

Website: www.skinkick.com 

ABOUT GLOBAL CAPITAL NETWORK

Global Capital Network (GCN) connects entrepreneurs and emerging companies with angel investors, venture capital firms, family offices and other capital providers through investor conferences and networking opportunities.

Website: www.globalcapitalnetwork.com

MEDIA & INVESTOR CONTACT

Maria Golseth
Email: [email protected]
Phone: 817-602-8367

SOURCE Hi-TECH Beauty Labs, Corp.